The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
Official Title: A Phase 2 Study of Dasatinib in Advanced Melanoma
Study ID: NCT00436605
Brief Summary: This phase II trial is studying how well dasatinib works in treating patients with stage III melanoma that cannot be removed by surgery or stage IV melanoma. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed Description: PRIMARY OBJECTIVES: I. Determine the objective response rate in patients with stage III unresectable or stage IV melanoma treated with dasatinib. II. Determine the progression-free survival of patients treated with this drug. SECONDARY OBJECTIVES: I. To assess the expression of targets of Dasatinib prior to treatment by obtaining pre-treatment biopsies or examining paraffin-embedded tissues from previous tumor resections. II. In selected patients (approximately 5-10) where tumor tissue is available pre-treatment and can be obtained post-treatment with Dasatinib (21 days after initiation of therapy), to determine if Dasatinib induces changes in expression of selected targets and downstream mediators, including MEK, ERK and RSK-1. III. To assess toxicity. OUTLINE: Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 4 weeks.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Yale University, New Haven, Connecticut, United States
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Name: Harriet Kluger
Affiliation: Yale University
Role: PRINCIPAL_INVESTIGATOR